19 June 2013
Keywords: genentech, drops, actimmune, renal, cell, carcinoma, decided
Article | 17 June 1996
Genentech has decided to discontinue the development of its Actimmune
(interferon gamma-1b) product as a treatment for renal cell ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
17 June 1996
24 June 1996
10 June 1996
© 2013 thepharmaletter.com